Therapy News and Research

RSS

ART safe and effective for treating combat-related symptoms of PTSD among veterans

Accelerated Resolution Therapy, or ART, is a brief, safe, and effective treatment for combat-related symptoms of post-traumatic stress disorder among veterans and U.S. service members, researchers at University of South Florida College of Nursing report in a new study. They found this newer treatment -- a combination of evidence-based psychotherapies and use of eye movements -- was shorter and more likely to be completed, than conventional therapies formally endorsed by the U.S. Department of Defense and the Veterans Administration.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the United States.

9 Dec 2013

Lawmakers close in on 'cease-fire' budget deal

Lawmakers are close to finding accord on a budget that would undo only a few parts of the government cuts known as "sequester." In addition, the proposed budget wouldn't lower the debt or change the costs involved with health care programs in addition to leaving other programs intact.

9 Dec 2013

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).

9 Dec 2013

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine on the investigational chimeric antigen receptor therapy, CTL019. Several studies being presented at the American Society of Hematology annual meeting add to the scientific understanding of CTL019 in the treatment of acute lymphoblastic leukemia and chronic lymphocytic leukemia and build on earlier research findings.

9 Dec 2013

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.

9 Dec 2013

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children's Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.

9 Dec 2013

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55th Annual Meeting of the American Society of Hematology in New Orleans.

9 Dec 2013

Revised Clinical Practice Guidelines on management of HCV published by EASL

The European Association for the Study of the Liver today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection. The EASL guidelines, which supersede the previous version published in 2011, are designed to help physicians and other healthcare providers optimise their management of patients with acute and chronic HCV.

9 Dec 2013

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.

9 Dec 2013

New form of gene therapy shows promising outcomes for "bubble boy" disease

Researchers reported promising outcomes data for the first group of boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a fatal genetic immunodeficiency also known as "bubble boy" disease, who were treated as part of an international clinical study of a new form of gene therapy. The mechanism used to deliver the gene therapy is designed to prevent the serious complication of leukemia that arose a decade ago in a similar trial in Europe, when one-quarter of boys treated developed the blood cancer.

9 Dec 2013

Penn researchers identify protein that could clear Alzheimer's plaques

The body is structured to ensure that any invading organisms have a tough time reaching the brain, an organ obviously critical to survival. Known as the blood-brain barrier, cells that line the brain and spinal cord are tightly packed, making it difficult for anything besides very small molecules to cross from the bloodstream into the central nervous system. While beneficial, this blockade also stands in the way of delivering drugs intended to treat neurological disorders, such as Alzheimer's.

9 Dec 2013

New study presents promising results for treatment of multiple myeloma

A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School, USA, and Karolinska Institutet, Sweden, presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.

9 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

Study shows VEEG telemetry monitoring with early cessation of AED therapy is safe, effective

Patients with epilepsy often undergo evaluation by concurrent video and EEG monitoring (vEEG) for therapeutic planning, including possible epilepsy surgery. Seizures during monitoring increase the diagnostic yield and requires the withdrawal of anticonvulsant drugs (AEDs) to allow seizures to occur.

9 Dec 2013

Researchers assess direct out-of-pocket costs for couples undergoing fertility treatment

From drug therapy to IVF, out-of pocket costs can range from $900 to $19,000 per treatment cycle, report researchers in The Journal of Urology

9 Dec 2013

Angioplasty may not provide additional benefits compared to drug therapy for patients with stable CAD

For patients with stable coronary artery disease (CAD) who are not experiencing a heart attack and an abnormal stress test, treatment of their narrowed arteries by the common procedure of angioplasty may not provide additional benefits compared to drug therapy alone.

9 Dec 2013

Low-income women less likely to receive breast cancer treatment

Women with interruptions in health insurance coverage or with low income levels had a significantly increased likelihood of failing to receive breast cancer care that is in concordance with recommended treatment guidelines, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

9 Dec 2013

Therapy News and Research

ART safe and effective for treating combat-related symptoms of PTSD among veterans

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Lawmakers close in on 'cease-fire' budget deal

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Revised Clinical Practice Guidelines on management of HCV published by EASL

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

New form of gene therapy shows promising outcomes for "bubble boy" disease

Penn researchers identify protein that could clear Alzheimer's plaques

New study presents promising results for treatment of multiple myeloma

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Study shows VEEG telemetry monitoring with early cessation of AED therapy is safe, effective

Researchers assess direct out-of-pocket costs for couples undergoing fertility treatment

Angioplasty may not provide additional benefits compared to drug therapy for patients with stable CAD

Low-income women less likely to receive breast cancer treatment

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News